4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Bi-objective Optimization for a Multi-period COVID-19 Vaccination Planning Problem

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This work investigates a new multi-period vaccination planning problem that simultaneously optimizes the total travel distance of vaccination recipients (service level) and the operational cost. An optimal plan determines, for each period, which vaccination sites to open, how many vaccination stations to launch at each site, how to assign recipients from different locations to opened sites, and the replenishment quantity of each site. We formulate this new problem as a bi-objective mixed-integer linear program (MILP). We first propose a weighted-sum and an ϵ -constraint methods, which rely on solving many single-objective MILPs and thus lose efficiency for practical-sized instances. To this end, we further develop a tailored genetic algorithm where an improved assignment strategy and a new dynamic programming method are designed to obtain good feasible solutions. Results from a case study indicate that our methods reduce the operational cost and the total travel distance by up to 9.3% and 36.6%, respectively. Managerial implications suggest enlarge the service capacity of vaccination sites to improve the performance of the vaccination program. The enhanced performance of our heuristic is due to the newly proposed assignment strategy and dynamic programming method. Our findings demonstrate that vaccination programs during pandemics can significantly benefit from formal methods, drastically improving service levels and decreasing operational costs.

          Related collections

          Most cited references78

          • Record: found
          • Abstract: not found
          • Article: not found

          A fast and elitist multiobjective genetic algorithm: NSGA-II

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

            It is urgent to understand the future of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) transmission. We used estimates of seasonality, immunity, and cross-immunity for betacoronaviruses OC43 and HKU1 from time series data from the USA to inform a model of SARS-CoV-2 transmission. We projected that recurrent wintertime outbreaks of SARS-CoV-2 will probably occur after the initial, most severe pandemic wave. Absent other interventions, a key metric for the success of social distancing is whether critical care capacities are exceeded. To avoid this, prolonged or intermittent social distancing may be necessary into 2022. Additional interventions, including expanded critical care capacity and an effective therapeutic, would improve the success of intermittent distancing and hasten the acquisition of herd immunity. Longitudinal serological studies are urgently needed to determine the extent and duration of immunity to SARS-CoV-2. Even in the event of apparent elimination, SARS-CoV-2 surveillance should be maintained since a resurgence in contagion could be possible as late as 2024.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SARS-CoV-2 vaccines in development

              Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
                Bookmark

                Author and article information

                Journal
                Omega
                Omega
                Omega
                Elsevier Ltd.
                0305-0483
                0305-0483
                16 February 2022
                16 February 2022
                : 102617
                Affiliations
                [a ]Logistics Engineering College, Shanghai Maritime University, Shanghai 201306, China
                [b ]School of Maritime Economics and Management, Dalian Maritime University, Dalian 116026, China
                [c ]School of Transportation and Logistics, Southwest Jiaotong University, Chengdu, Sichuan 611756, China
                [d ]CIRRELT, Université Laval, Canada research chair in integrated logistics, Canada
                Author notes
                [* ]Corresponding author.:
                Article
                S0305-0483(22)00026-3 102617
                10.1016/j.omega.2022.102617
                8848572
                35185262
                883f69fb-7277-4703-b6c1-6b1daf43b8a0
                © 2022 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 27 August 2021
                : 12 February 2022
                : 12 February 2022
                Categories
                Article

                covid-19,vaccination planning,multi-period location-allocation,multi-objective optimization,mixed-integer linear programming

                Comments

                Comment on this article